Are unknown co-medications, over-the-counter and off-label drug use still problems among people living with HIV? Results from a transversal survey in 23 centres in France.
J Antimicrob Chemother
; 78(11): 2731-2734, 2023 11 06.
Article
em En
| MEDLINE
| ID: mdl-37757452
ABSTRACT
INTRODUCTION:
Polypharmacy can lead to drug-drug interactions (DDIs), especially with ART. The burden of co-medications, including over-the-counter (OTC) drugs and self-medications, could be underestimated. We aimed to investigate the proportion of people living with HIV (PLHIV) with declared and undeclared co-medications, as well as their potential burden.METHODS:
We conducted a national, multicentre, 1 week cross-sectional study between 10 December and 16 December 2019 in 23 French hospitals amongst consecutive adult PLHIV presenting for a routine outpatient visit. A standardized questionnaire filled in by the physicians assessed all medications and other active chemical substances taken by the PLHIV.RESULTS:
Overall we enrolled 496 participants from 23 centres. Median age was 50.6 years; ART regimens included an integrase inhibitor in 61% (nâ=â302), an NNRTI in 34% (nâ=â169) and a PI in 14% (nâ=â70) of the cases. Co-medications involved 392 (79%) PLHIV, among which 85 (17%) received polypharmacy (≥5 medications). Previously unknown co-medications or other active substances were found for 32% (nâ=â159) of the participants. Corticosteroids (9%, nâ=â46) and proton pump inhibitors (10%, nâ=â50) were frequently administered. These co-medications did not differ according to age range. Illegal drug use was declared by 11% (nâ=â54) and OTC drugs by 23% (nâ=â113) of PLHIV. Potential DDIs were discovered for 11% (nâ=â53), leading to treatment modifications in 47% (25/53) of cases.CONCLUSIONS:
Potential DDIs that lead to therapeutic modifications remain significant whatever the age of PLHIV. More devoted time to identify co-medications and OTC treatment is needed in all PLHIV.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Infecções por HIV
/
Uso Off-Label
Tipo de estudo:
Observational_studies
Limite:
Adult
/
Humans
/
Middle aged
País/Região como assunto:
Europa
Idioma:
En
Revista:
J Antimicrob Chemother
Ano de publicação:
2023
Tipo de documento:
Article
País de afiliação:
França